ALK and neoplasm: For instance, Pembrolizumab has significantly improved the 5-year survival rate of advanced NSCLC patients and has been approved for first-line treatment in patients with PD-L1 tumor proportion score (TPS) ≥1% and without EGFR/ALK gene alterations (38, 39).